WASHINGTON, Feb. 13 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases.
The notice was published in the Federal Register on Feb. 13 by Richard U. Rodriguez, Supervisory Technology Transfer and Patent Specialist, Technology Transfer Center, National Cancer Institute.
Summary: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the...